Article
作者: Dundar, Nihal Olgaç ; Coskun, Aysenur ; Öztürk, Selcan ; Bektas, Ömer ; Kumandas, Sefer ; Yılmaz, Ünsal ; Ibis, Ipek Burcu Parlak ; Serdaroglu, Ayşe ; Topçu, Yasemin ; Gunay, Cagatay ; Direk, Meltem Cobanogullari ; Yilmaz, Unsal ; Okuyaz, Çetin ; Arslan, Mutluay ; Kayilioglu, Hulya ; Cankurt, Ilknur ; Gokben, Sarenur ; Gümüş, Hakan ; Arhan, Ebru ; Ozpinar, Esra ; Yilmaz, Sanem ; Kart, Pınar Özkan ; Kilic, Betul ; Kırkgöz, Hilal ; Karaoğlu, Pakize ; Yildirim, Nalan ; Canpolat, Mehmet ; Olculu, Cemile Busra ; Cansu, Ali ; Oktay, Secil ; Akkoyunlu, Deniz Sunnetci ; Polat, Muzaffer ; Dogan, Dilara Ece Toprak ; Serdaroglu, Esra ; Yilmaz, Sema Bozkaya ; Yildirim, Mirac ; Turk, Emre ; Günay, Çağatay ; Hiz, Semra ; Kılıç, Betül ; Per, Hüseyin ; Uzan, Gamze Sarıkaya ; İbiş, İpek Burcu Parlak ; Bektas, Omer ; Orak, Ali ; Hız, Semra ; Yıldırım, Miraç ; Ozpınar, Esra ; Serin, Hepsen Mine ; Kart, Pinar Ozkan ; Topcu, Yasemin ; Kömür, Mustafa ; Kayılıoglu, Hulya ; Yılmaz, Sema Bozkaya ; Unay, Bulent ; Güleç, Ayten ; Ersoy, Özlem ; Gencpinar, Pinar ; Cine, Naci ; Gulec, Ayten ; Gencpınar, Pınar ; Tekgul, Hasan ; Çelik, Neslihan ; Kara, Bulent ; Aydin, Kursad ; Tosun, Ayse ; Cerci, Cisil ; Direk, Meltem Çobanoğulları ; Teber, Serap ; Kanmaz, Seda ; Ayanoglu, Muge ; Aktan, Gul ; Atas, Yavuz ; Uzan, Gamze Sarikaya ; Ozturk, Selcan ; Türk, Emre ; Coşkun, Ayşenur ; Ersoy, Ozlem ; Celik, Neslihan ; Yıldırım, Nalan ; Dundar, Nihal Olgac ; Per, Huseyin ; Gumus, Hakan ; Kumandaş, Sefer ; Aydın, Kursad ; Serdaroglu, Ayse ; Kirkgoz, Hilal ; Akyol, Duygu ; Yildiz, Nihal ; Okuyaz, Cetin ; Komur, Mustafa ; Unalp, Aycan ; Cankurt, İlknur ; Yıldız, Nihal ; Hirfanoglu, Tugba ; Yılmaz, Sanem ; Yis, Uluc
OBJECTIVETo evaluate the etiology-specific diagnosis of early-onset developmental epileptic encephalopathies (EO-DEEs) in a nationwide Turkish cohort to determine the implications for therapeutic management.METHODSThe cohort comprised 1450 patients who underwent EO-DEE. The utility of genetic testing was assessed with respect to the initial phases of next generation sequencing (NGS) (2005-2013) and the current NGS era (2014-2022). A predefined four-stepwise diagnostic model was evaluated using cost-effectiveness analysis. The diagnostic and potential therapeutic yields of the genetic tests were subsequently determined.RESULTSGene-related EO-DEEs were identified in 48.3 % (n = 701) of the cohort: non-structural genetic (62.6 %), metabolic genetic (15.1 %), and structural genetic (14.1 %). The most common nonstructural genetic variants were SCN1A (n = 132, 18.8 %), CDKL5 (n = 30, 4.2 %), STXBP1 (n = 21, 2.9 %), KCNQ2 (n = 21, 2.9 %), and PCDH19 (n = 17, 2.4 %). The rate of ultra-rare variants (< 0.5 %) was higher in the NGS era (52 %) than that in the initial phase (36 %). The potential therapeutic yields with precision therapy and antiseizure drug modification were defined in 34.5 % and 56.2 % in genetic-EO-DEEs, respectively. The diagnostic model provided an etiology-specific diagnosis at a rate of 78.7 %: structural (nongenetic) (31.4 %), genetic (38.5 %), metabolic (6.1 %), and immune-infectious (2.8 %). Based on a cost-effectiveness analysis, the presented diagnostic model indicated the early implementation of whole-exome sequencing for EO-DEEs.SIGNIFICANCEIn the present cohort, the higher rate (48.3 %) of gene-related EO-DEE diagnoses in the NGS era provides a potential therapeutic management plan for more patients.